Transient cardiac arrhythmias related to lopinavir/ritonavir in two patients with HIV infection
Santosh K. Chaubey A F , Ashim K. Sinha A , Elizabeth Phillips B , Darren B. Russell C D and Henrik Falhammar A EA Department of Medicine, Cairns Base Hospital, PO Box 902, Cairns, Qld 4870, Australia.
B Department of Clinical, Immunology and Immunogenetics, Centre for Clinical Pharmacology and Infectious Diseases, Royal Perth Hospital, 2nd Floor North Block, Wellington Street, Perth, WA 6000, Australia.
C Cairns Sexual Health Service, Cairns Base Hospital, PO Box 902, Cairns, Qld 4870, Australia.
D Melbourne School of Population Health, Level 5, 207 Bouverie Street, The University of Melbourne, Vic. 3010, Australia.
E Department of Molecular Medicine and Surgery, D2:04, Karolinska Institute, Stockholm, 171 76, Sweden.
F Corresponding author. Email: drchaubeysk@rediffmail.com
Sexual Health 6(3) 254-257 https://doi.org/10.1071/SH09005
Submitted: 9 January 2009 Accepted: 29 May 2009 Published: 3 August 2009
Abstract
A 42-year-old Thai man was administered the combination drugs liponavir/ritonavir and abacavir/lamivudine. On day 3 he was admitted and his electrocardiogram demonstrated sinus arrest with junctional escape rhythm with a rate of 42 min−1. Three days after stopping the medication he reverted to normal sinus rhythm. A 55-year-old Caucasian man was admitted to hospital with triple vessel disease. He had a permanent pace maker inserted 4 years previously for Mobitz type II AV block detected on stress electrocardiogram, which developed 1 month after initiation of lopinavir/ritonavir. These two cases highlight the importance of considering lopinavir/ritonavir induced arrhythmias when dealing with HIV-positive individuals.
Additional keyword: antiretroviral therapy.
[1]
[2] Kikuchi Y, Genka I, Ishizaki A, Sunagawa K, Yasuoka A, Oka S. Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002; 35 488–90.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[3] Yotsumoto M, Kitano K, Saito H. Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS. AIDS 2005; 19 1547–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[4] Jimenez FJ, Pinilla J, Repiso M, Labarga P. Complete autriculoventricular block in a patient treatment with lopinavir/ritonavir. Enferm Infect Microbiol Clin 2002; 20 418.
[5] Busti AJ, Tsikouris JP, Peeters MJ, Das SR, Canham RM, Abdullah SM, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med 2006; 7 317–22.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[6] Grody WW, Cheng L, Lewis W. Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990; 66 203–6.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[7] Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet 2005; 365 682–6.
| CAS | PubMed |
[8] Schulze-Bahr E, Neu A, Friederich P, Kaupp UB, Breithardt G, Pongs O, et al. Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest 2003; 111 1537–45.
| CAS | PubMed |
[9] Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003; 112 1019–28.
| CAS | PubMed |
[10] Bezzina CR, Shimizu W, Yang P, Koopmann TT, Tanck MW, Miyamoto Y, et al. Common sodium channel promoter haplotype in Asian subjects underlies variability in cardiac conduction. Circulation 2006; 113 338–44.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
[11] Shimizu W. Clinical impact of genetic studies in lethal inherited cardiac arrhythmias. Circ J 2008; 72 1926–36.
| Crossref | GoogleScholarGoogle Scholar | CAS | PubMed |
